Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program

Volume: 6, Issue: 4, Pages: 382 - 389
Published: Apr 15, 2020
Abstract
Weight management medications can significantly increase patients' chances of achieving a clinically meaningful weight loss if patients persist with treatment. This retrospective observational study of de-identified medical records of 311 patients is the first real-world study examining persistence with liraglutide 3.0 mg in Canada, and also investigates associations between the SaxendaCare® patient support program and persistence and weight...
Paper Details
Title
Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program
Published Date
Apr 15, 2020
Volume
6
Issue
4
Pages
382 - 389
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.